Short answer
Protara Therapeutics, Inc. (TARA) filed an 8-K current report with the SEC on February 24, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events). Standard Reg FD "furnished not filed" disclaimer: no investor-actionable content disclosed in this section.
Protara Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Standard Reg FD "furnished not filed" disclaimer: no investor-actionable content disclosed in this section
Item 8.01 · Other Events
- BCG-Unresponsive cohort: 65.7% CR at any time; 68.2% CR at 6 months; 100% of 12-month responders maintained CR through month 12
- BCG-Naïve cohort: stronger durability, 72.4% CR at any time; 57.9% CR at 12 months; 100% (11/11) maintained CR from months 9–12
- Re-induction highly effective: 61.5% of BCG-Unresponsive and 66.7% of BCG-Naïve initial non-responders converted to CR
- Clean safety profile: no Grade 3+ TRAEs, no serious adverse events, zero discontinuations; key differentiator vs. competitors
- BCG-Unresponsive registrational cohort enrollment to complete H2 2026; ADVANCED-3 registrational trial in BCG-Naïve patients to initiate H2 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Protara Therapeutics, Inc. 8-K filings
Get the next TARA 8-K as it lands
Follow TARA for push alerts, or ask the research agent what this filing means.